Prognostic value of the plasminogen activation system in patients with gastric carcinoma

Cancer

Volumn 77, Issue 6, 1996, Pages 1035-1043

  Ganesh, Sjam ^b   Sier, Cornelis F M ^b   Heerding, Martine M ^b   Van Krieken, Johan H J M ^a   Griffioen, Gerrit ^b   Welvaart, Kees ^a   Van De Velde, Cornelis J H ^a   Verheijen, Jan H ^a   Lamers, Cornelis B H W ^b   Verspaget, Hein W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Building 1 ^*

Author keywords

gastric cancer; normal mucosa; plasminogen activator; plasminogen activator inhibitor; prognosis; survival

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STOMACH CARCINOGENESIS; STOMACH CARCINOMA;

AGED; FEMALE; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TISSUE PLASMINOGEN ACTIVATOR; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 13344281003     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960315)77:6<1035::AID-CNCR5>3.0.CO;2-G     Document Type: Article

References (57)

1. Moreno González E, Arias Diaz J, Gómez Gutiérrez M, Calleja Kempin J, Hidalgo Pascual M, Jover Navalón JM, et al. Lymphatic dissemination of gastric cancer - therapeutic implications. Hepatogastroenterology 1989;36:66-70.
2. Bozzetti F, Regalia E, Bonfanti G, Doci R, Ballarini D, Gennari L. Early and late results of extended surgery for cancer of the stomach. Br J Surg 1990;77:53-6.
3. Akoh JA, Sedgwick DM, Macintyre IMC. Improving results in the treatment of gastric cancer: an 11-year audit. Br J Surg 1991;78:349-51.
4. Harrison JC, Dean PJ, van der Zwaag R, El-Zeky F, Wruble LD. Adenocarcinoma of the stomach with invasion limited to the muscularis propria. Hum Pathol 1991;22:111-7.
5. Nakamura K, Ueyama T, Yao T, Xin Xuan Z, Ambe K, Adachi Y, et al. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer 1992;70:1030-7.
6. Oliveira P, Nobre-Leitão C, Chaves P. Early gastric cancer: an analysis of 44 cases with emphasis on the prognostic significance of the macroscopic and microscopic growth patterns. J Surg Oncol 1992;51:118-21.
7. Rohde H, Gebbensleben B, Bauer P, Stützer H, Zieschang J. Has there been any improvement in the staging of gastric cancer? Cancer 1989;64:2465-81.
8. Roder JD, Böttcher K, Siewert RJ, Busch R, Hermanek P, Meyer HJ. Prognostic factors in gastric carcinoma. Cancer 1993;72:2089-97.
9. Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 1993;85:1839-44.
10. Atiq OT, Kelsen DP, Shiu MH, Saltz L, Tong W, Niedzwiecki D, et al. Phase II trial of postoperatieve adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemo-therapy in patients with resected gastric cancer. J Clin Oncol 1993;11:425-33.
11. Rougier Ph, Lasser Ph, Ducreux M, Mahjoubi M, Bognel C, Elias D. Preoperarive chemotherapy of locally advanced gastric cancer. Ann Oncol 1994:5(3 Suppl):59-68.
12. Danø; K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985;44:139-266.
13. Hart DA. Dysregulation of plasminogen activators in cancer - potential role in invasion, metastasis and as a prognostic indicator. Fibrinolysis 1992;6(1 Suppl):11-5.
14. Schultz RM, Yu H, Zhang JY. The role of urokinase and urokinase inhibitor in tumour cell metastasis. Fibrinolysis 1992;6(1 Suppl):23-9.
15. Duffy MJ. Urokinase-type plasminogen activator and malignancy. Fibrinolysis 1993;7:295-302.
16. de Bruin PAF, Griffioen G, Verspaget HW, Verheijen JH, Lamers CBHW. Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res 1987;47:4654-7.
17. Nishino N, Aoki K, Tokura Y, Sakaguchi S, Takada Y, Takada A. The urokinase type of plasminogen activator in cancer of digestive tracts. Tromb Res 1988;50:527-35.
18. Sier CFM, Verspaget HW, Griffioen G, Verheijen JH, Quax PHA, Dooijewaard G, et al. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implication of urokinase in colorectal carcinogenesis. Gastroenterology 1991;101:1522-8.
19. Sumiyoshi K, Baba S, Sakaguchi S, Urano T, Takada Y, Takada A. Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis. Thromb Res 1991;63:59-71.
20. Takai S, Yamamura M, Tanaka K, Kawanishi H, Tsuji M, Nakane Y, et al. Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining. Int J Cancer 1991;48:20-7.
21. Tanaka N, Fukao H, Ueshima S, Okada K, Yasutomi M, Matsuo O. Plasminogen activator inhibitor 1 in human carcinoma tissues. Int J Cancer 1991;48:481-4.
22. Umehara Y, Kimura T, Yoshida M, Oba N, Harada Y. Relationship between plasminogen activators and stomach carcinoma stage. Acta Oncol 1991;30:815-8.
23. Nakamura M, Konno H, Tanaka T, Maruo Y, Nishino N, Aoki K, et al. Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues. Thromb Res 1992;65:709-19.
24. Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Yong Li P, et al. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 1993;53:3198-206.
25. Sier CFM, Verspaget HW, Griffioen G, Ganesh S, Vloedgraven HJM, Lamers CBHW. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut 1993;34:80-5.
26. Jänicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 1991;17:303-12.
27. Duffy MJ, Reilly D, Nolan N, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase plasminogen activator, a strong and independent prognostic marker in breast cancer. Fibrinolysis 1992;6(4 Suppl):55-7.
28. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994;69:398-405.
29. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Kramer MD, Jänicke F, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994; 12:1648-58.
30. Ganesh S, Sier CFM, Griffioen G, Vloedgraven HJM, de Boer A, Welvaart K, et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994;54:4065-71.
31. Ganesh S, Sier CFM, Heerding MM, Griffioen G, Lamers CBHW, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994;344:401-2.
32. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP, et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancer 1994;344:583-4.
33. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, Sumiyoshi A. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 1992;50:871-3.
34. Pedersen H, Brünner N, Francis D, Østerlind K, Rønne E, Hansen HH, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54:4671-5.
35. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994;54:2900-7.
36. Plebani M, Herszènyi L, Cardin R, Roveroni G, Carraro P, Paoli MD, et al. Cysteine and serine proteases in gastric cancer. Cancer 1995;76:367-75.
37. Hermanek P, Sobin LH, editors. UICC TNM classification of malignant tumours. 4th ed. 2nd rev. Berlin: Springer-Verlag, 1992.
38. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965;64:31-49.
39. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
40. Binnema DJ, van Iersel JJL, Dooijewaard G. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromb Res 1986;43:569-77.
41. Rijken DC, van Hinsbergh VWM, Sens EHC. Quantitation of tissue-type plasminogen activator in human endothelial cell cultures by use of an enzyme immunoassay. Thromb Res 1984;33:145-53.
42. Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982;48:266-9.
43. Cox DR. Regression models and life-tables. J R Stat Soc(B) 1972;34:187-220.
44. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA 1958;53:457-81.
45. Gall FP, Hermanek P. New aspects in the surgical treatment of gastric carcinoma - a comparative study of 1636 patients operated on between 1969 and 1982. Eur J Surg Oncol 1985;11:219-25.
46. Noguchi Y, Imada T, Matsumoto A, Coit DG, Brennan MF. Radical surgery for gastric cancer. A review of the Japanese experience. Cancer 1989;64:2053-62.
47. Sue-Ling HM, Johnston D, Martin IG, Dixon MF, Lansdown MRJ, McMahon MJ, et al. Gastric cancer: a curable disease in Britain. BMJ 1993;307:591-6.
48. Kampschöer GHM, Nakajima T, Velde van de CJH. Changing patterns in gastric adenocarcinoma. Br J Surg 1989;76:914-6.
49. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF, Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.
50. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104:510-3.
51. Iwasaki K, Torisu M, Fujimura T. Malignant tumor and eosinophils. I. Prognostic significance in gastric cancer. Cancer 1986;58;1321-7.
52. Pretlow TP, Keith EF, Cryar AK, Bartolucci AA, Pitts AM, Pretlow II TG, et al. Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res 1983; 43:2997-3000.
53. Sier CFM, Vloedgraven HJM, Ganesh S, Griffioen G, Quax PHA, Verheijen JH, et al. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 1994;107:1449-56.
54. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995;13:2084-93.
55. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HR. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 1988;48:1348-9.
56. Coma del Corral MJ, Pardo-Mindan FJ, Razquin S, Ojeda C. Risk of cancer in patients with gastric dysplasia. Follow-up study of 67 patients. Cancer 1990;65:2078-85.
57. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 1992;52:6735-40.